Name: ELTX ELI-002 7P Catalyst
Start: 2026-03-31

Elicio Therapeutics, Inc.

Catalyst AI-extracted

ELI-002 7P

adjuvant mKRAS-driven pancreatic ductal adenocarcinoma

Resolved

98days ago

Catalyst readout · ~ Mar 31, 2026 estimated

What's at stake A key catalyst for ELI-002 7P (adjuvant mKRAS-driven pancreatic ductal adenocarcinoma) is expected ~ Mar 31, 2026.

Primary source · SEC 8-K verified 15h ago

“Initiate Phase 3 Study in Adjuvant PDAC Post FDA alignment, initiate Phase 3, subject to funding”